RAPT Therapeutics - RAPT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $24.67
  • Forecasted Upside: 685.56%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.14
▲ +0.05 (1.62%)

This chart shows the closing price for RAPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RAPT Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAPT

Analyst Price Target is $24.67
▲ +685.56% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for RAPT Therapeutics in the last 3 months. The average price target is $24.67, with a high forecast of $41.00 and a low forecast of $4.00. The average price target represents a 685.56% upside from the last price of $3.14.

This chart shows the closing price for RAPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 polled investment analysts is to hold stock in RAPT Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2024Wolfe ResearchReiterated RatingOutperform ➝ Peer PerformLow
5/10/2024GuggenheimDowngradeBuy ➝ NeutralLow
5/10/2024BarclaysDowngradeOverweight ➝ Equal Weight$13.00 ➝ $4.00Low
4/10/2024HC WainwrightReiterated RatingNeutralLow
3/27/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$15.00 ➝ $13.00Low
2/22/2024UBS GroupDowngradeBuy ➝ Neutral$61.00 ➝ $10.00Low
2/21/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
2/21/2024BarclaysLower TargetOverweight ➝ Overweight$35.00 ➝ $13.00Low
2/21/2024SVB LeerinkDowngradeOutperform ➝ Market Perform$42.00 ➝ $10.00Low
2/21/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$35.00 ➝ $15.00Low
2/21/2024HC WainwrightDowngradeBuy ➝ NeutralLow
2/20/2024Cantor FitzgeraldDowngradeOverweight ➝ NeutralN/A
2/16/2024Evercore ISIInitiated CoverageOutperformLow
2/15/2024Wolfe ResearchInitiated CoverageOutperform$39.00Low
11/30/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$32.00 ➝ $35.00Low
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00Low
9/14/2023Berenberg BankInitiated CoverageBuy$34.00Low
8/16/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$39.00 ➝ $32.00Low
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00Low
8/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$28.00 ➝ $31.00Low
8/8/2023Stifel NicolausInitiated CoverageBuy$40.00Low
6/15/2023BarclaysInitiated CoverageOverweight$35.00Low
5/12/2023HC WainwrightLower Target$43.00 ➝ $41.00Low
3/30/2023HC WainwrightReiterated RatingBuy$43.00Low
3/21/2023JPMorgan Chase & Co.Lower TargetOverweight$48.00 ➝ $42.00Low
3/21/2023HC WainwrightReiterated RatingBuy$43.00Low
3/15/2023The Goldman Sachs GroupLower TargetBuy$27.00 ➝ $23.00Low
3/15/2023GuggenheimLower TargetBuy$55.00 ➝ $48.00Low
3/15/2023Cantor FitzgeraldLower Target$44.00 ➝ $40.00Low
3/15/2023HC WainwrightLower TargetBuy$50.00 ➝ $43.00Low
1/4/2023Wells Fargo & CompanyLower TargetOverweight$55.00 ➝ $48.00Low
1/4/2023GuggenheimInitiated CoverageBuy$55.00Low
12/8/2022Piper SandlerLower Target$34.00 ➝ $33.00Low
12/1/2022The Goldman Sachs GroupInitiated CoverageBuy$27.00Low
11/14/2022HC WainwrightLower TargetBuy$53.00 ➝ $50.00Low
11/10/2022Piper SandlerBoost TargetOverweight$30.00 ➝ $34.00Low
9/21/2022Capital One FinancialInitiated CoverageOverweight$48.00Low
8/12/2022HC WainwrightBoost TargetBuy$50.00 ➝ $53.00Low
8/11/2022SVB LeerinkLower TargetOutperform$49.00 ➝ $48.00Low
6/23/2022HC WainwrightLower TargetBuy$56.00 ➝ $50.00Low
5/12/2022Piper SandlerLower Target$52.00 ➝ $30.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/16/2022Roth CapitalReiterated RatingBuyHigh
3/14/2022HC WainwrightReiterated RatingBuy$56.00High
3/11/2022Piper SandlerLower TargetOverweight$61.00 ➝ $52.00Low
3/11/2022Wells Fargo & CompanyLower TargetOverweight$65.00 ➝ $55.00Low
12/9/2021JPMorgan Chase & Co.Initiated CoverageOverweight$61.00High
11/16/2021Cantor FitzgeraldLower TargetOverweight$71.00 ➝ $58.00High
10/4/2021SVB LeerinkReiterated RatingBuyMedium
8/30/2021HC WainwrightReiterated RatingBuy$56.00Medium
8/12/2021SVB LeerinkInitiated CoverageOutperform$49.00High
6/23/2021HC WainwrightBoost TargetBuy$29.00 ➝ $56.00Low
6/20/2021Piper SandlerInitiated CoverageOverweight$61.00Low
6/14/2021Wells Fargo & CompanyBoost TargetOverweight$30.00 ➝ $65.00High
6/14/2021Roth CapitalBoost TargetPositive ➝ Buy$38.00 ➝ $72.00High
6/14/2021Cantor FitzgeraldBoost TargetOverweight$51.00 ➝ $71.00High
5/26/2021Cantor FitzgeraldReiterated RatingOverweightLow
5/17/2021HC WainwrightLower TargetBuy$32.00 ➝ $29.00Low
3/12/2021HC WainwrightBoost TargetBuy$30.00 ➝ $32.00Low
11/17/2020BMO Capital MarketsLower TargetOutperform$51.00 ➝ $45.00Low
11/17/2020HC WainwrightLower TargetBuy$42.00 ➝ $30.00Medium
10/21/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$40.00 ➝ $51.00High
8/14/2020HC WainwrightBoost TargetBuy$40.00 ➝ $42.00High
8/14/2020BMO Capital MarketsBoost TargetOutperform$35.00 ➝ $40.00High
7/27/2020Cantor FitzgeraldBoost TargetOverweight$37.00 ➝ $51.00High
7/13/2020Wells Fargo & CompanyBoost TargetOverweight$33.00 ➝ $40.00High
6/1/2020HC WainwrightInitiated CoverageBuy$40.00High
5/18/2020Cantor FitzgeraldInitiated CoverageOverweight$37.00High
4/13/2020Roth CapitalInitiated CoverageBuy$38.00Medium
2/11/2020UBS GroupReiterated RatingPositive ➝ Buy$44.00Low
12/4/2019UBS GroupBoost TargetBuy$26.00 ➝ $31.00High
11/25/2019UBS GroupInitiated CoverageBuy$26.00 ➝ $26.00High
11/25/2019Wells Fargo & CompanyInitiated CoverageOutperform$33.00High
11/25/2019BMO Capital MarketsInitiated CoverageOutperform$35.00 ➝ $35.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.32 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 6 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 6 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/25/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
RAPT Therapeutics logo
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More

Today's Range

Now: $3.14
Low: $3.06
High: $3.28

50 Day Range

MA: $5.41
Low: $3.09
High: $8.54

52 Week Range

Now: $3.14
Low: $2.99
High: $27.35

Volume

674,100 shs

Average Volume

1,039,749 shs

Market Capitalization

$109.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of RAPT Therapeutics?

The following equities research analysts have issued research reports on RAPT Therapeutics in the last twelve months: Barclays PLC, Berenberg Bank, Cantor Fitzgerald, Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for RAPT.

What is the current price target for RAPT Therapeutics?

9 Wall Street analysts have set twelve-month price targets for RAPT Therapeutics in the last year. Their average twelve-month price target is $24.67, suggesting a possible upside of 685.6%. HC Wainwright has the highest price target set, predicting RAPT will reach $41.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $4.00 for RAPT Therapeutics in the next year.
View the latest price targets for RAPT.

What is the current consensus analyst rating for RAPT Therapeutics?

RAPT Therapeutics currently has 9 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RAPT, but not buy more shares or sell existing shares.
View the latest ratings for RAPT.

What other companies compete with RAPT Therapeutics?

How do I contact RAPT Therapeutics' investor relations team?

RAPT Therapeutics' physical mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 489-9000 and its investor relations email address is [email protected]. The official website for RAPT Therapeutics is www.rapt.com. Learn More about contacing RAPT Therapeutics investor relations.